LEADER 04040nam 22006015 450 001 9910349438503321 005 20240118133717.0 010 $a3-030-26736-9 024 7 $a10.1007/978-3-030-26736-0 035 $a(CKB)4100000009678364 035 $a(MiAaPQ)EBC5968946 035 $a(DE-He213)978-3-030-26736-0 035 $a(PPN)258306858 035 $a(EXLCZ)994100000009678364 100 $a20191025d2019 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPhage Therapy: A Practical Approach /$fedited by Andrzej Górski, Ryszard Mi?dzybrodzki, Jan Borysowski 205 $a1st ed. 2019. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019. 215 $a1 online resource (384 pages) 311 $a3-030-26735-0 320 $aIncludes bibliographical references. 327 $aPart I: Bacteriophages as antibacterialagents -- Chapter 1:Production of PhageTherapeutics and Formulations ? InnovativeApproaches -- Chapter 2:Phagepharmacokinetics: relationship with administrationroute -- Chapter 3:BacterialResistance to Phage and itsImpact on Clinical Therapy -- Part II: Bacteriophages and the immune system -- Chapter 4:Phageinteraction with the mammalianimmune system -- Chapter 5:Humoralimmuneresponse to phage-basedtherapeutics -- Part III:Use of bacteriophages to combat bacterial infections -- Chapter 6:How to achieve a goodphage therapy clinical trial? -- Chapter 7: Perspectives on the RenewedInterest in the United States -- Chapter 8:Phage Therapy in Orthopaedic Implant-associated Infections -- Chapter 9:The use of bacteriophages in animalhealth and food protection -- Chapter 10:Combiningbacteriophages with otherantibacterialagents to combatbacteria -- Chapter 11: Phage therapy of infectious biofilms: Challenges and strategies -- Part IV:Phage therapy ? regulatory and ethical aspects -- Chapter 12:Regulatory Considerations for Bacteriophage Therapy Products -- Chapter 13:Developing phagesintomedicines for Europe -- Chapter 14: Phagetherapy in Europe: Regulatory and intellectualpropertyprotectionissues -- Chapter 15:Ethics of phagetherapy -- Part V: Bacteriophage-derived antibacterial agents -- Chapter 16: NovelAlternative to Antibiotics. 330 $aThis book gives a detailed yet clear insight into the current state of the art of the therapeutic application of bacteriophages in different conditions. The authors bring in their practical expertise within their respective fields of expertise and provide an excellent overview of the potential and actual use of phage therapy. Topics like economic feasibility compared to traditional antibiotics and also regulatory issues are discussed in far detail. This new volume is therefore a valuable resource for individuals engaged in the medical application of novel phage therapies. 606 $aMedical microbiology 606 $aMolecular biology 606 $aMedical Microbiology$3https://scigraph.springernature.com/ontologies/product-market-codes/B16003 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 606 $aBacteriòfags$2thub 606 $aMicrobiologia mèdica$2thub 608 $aLlibres electrònics$2thub 615 0$aMedical microbiology. 615 0$aMolecular biology. 615 14$aMedical Microbiology. 615 24$aMolecular Medicine. 615 7$aBacteriòfags 615 7$aMicrobiologia mèdica 676 $a579.26 676 $a579.26 702 $aGórski$b Andrzej$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aMi?dzybrodzki$b Ryszard$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aBorysowski$b Jan$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910349438503321 996 $aPhage Therapy: A Practical Approach$91995453 997 $aUNINA